LON:HIK

Hikma Pharmaceuticals (HIK) Share Forecast, Price & News

GBX 2,099

-11.00 (-0.52%)

(As of 03:19 PM ET)

Compare

Today's Range: 2,082
▼
2,111
50-Day Range: 1,810
▼
2,205
52-Week Range: 1,174.50
▼
2,222

Volume: 68,278 shs
Average Volume: 424,794 shs
Market Capitalization: £4.64 billion

P/E Ratio: 3,960.38
Dividend Yield: 2.33%
Price Target: GBX 1,939.17

Profile Analyst Ratings Chart Competitors Dividend Insider Trades Headlines Sustainability

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 7.8% Downside
GBX 1,939.17 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.17
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

1.3

Analyst's Opinion

Consensus Rating
Hikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 1,939.17, Hikma Pharmaceuticals has a forecasted downside of 7.8% from its current price of GBX 2,104.
Amount of Analyst Coverage
Hikma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for HIK.

0.8

Dividend Strength

Dividend Yield
Hikma Pharmaceuticals pays a meaningful dividend of 2.37%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Hikma Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Hikma Pharmaceuticals is 9,245.28%. Payout ratios above 75% are not desirable because they may not be sustainable.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Hikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Hikma Pharmaceuticals is -2.61.

1.8

News and Social Media Coverage

News Sentiment
Hikma Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Hikma Pharmaceuticals this week, compared to 3 articles on an average week.
MarketBeat Follows
2 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.73% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.98% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hikma Pharmaceuticals is 3,969.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.97.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hikma Pharmaceuticals is 3,969.81, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 97.60.
Price to Earnings Growth Ratio
Hikma Pharmaceuticals has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Hikma Pharmaceuticals has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.

HIK Price History

30 days | 90 days | 365 days | Advanced Chart

HIK Stock News Headlines

September 17, 2023 | americanbankingnews.com

Hikma Pharmaceuticals PLC (LON:HIK) Receives Average Recommendation of "Moderate Buy" from Analysts

September 16, 2023 | americanbankingnews.com

Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average of $1,891.33

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 7, 2023 | marketwatch.com

Arecor Therapeutics Partner Hikma Advances on Review of AT307 in US

September 6, 2023 | tmcnet.com

Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook

August 31, 2023 | foxnews.com

Generic versions of Vyvanse released to address ADHD medicine shortage in US

August 31, 2023 | msn.com

M&S to make FTSE 100 comeback

August 30, 2023 | ft.com

Marks and Spencer to return to FTSE 100 after 4-year absence

September 22, 2023 | Altimetry (Ad)

Fraud Expert: Dump these three popular stocks

A major (and legal) market manipulation scheme is about to play out. It could cost you a fortune – or double your money. You choose. Find out what he knows, here.

August 30, 2023 | finance.yahoo.com

Marks & Spencer Makes a Return to the FTSE 100 as Hiscox Loses Out in Reshuffle

August 25, 2023 | finance.yahoo.com

Inotropic Agents Global Market Report 2023

August 24, 2023 | uk.finance.yahoo.com

Generic Injectables Global Market Report 2023

August 23, 2023 | msn.com

Resurgent M&S set for FTSE 100 return but builder Persimmon heads for the exit

August 23, 2023 | msn.com

Dechra Pharmaceuticals set for promotion to FTSE 100 alongside M&S

August 23, 2023 | yahoo.com

FTSE 100 Live: London top flight seen higher ahead of PMI reading, US bank downgrades, Klarna sales boom

August 22, 2023 | msn.com

M&S set for FTSE 100 return but builder Persimmon heading for exit

August 22, 2023 | benzinga.com

Prefilled Syringes Market Size & Share to Surpass $10.59 Billion by 2030 | Vantage Market Research

August 22, 2023 | msn.com

M&S set for promotion back into Ftse-100 as it stages recovery

August 3, 2023 | msn.com

Hikma reports strong H1 performance, raises generics drugs guidance

August 3, 2023 | finance.yahoo.com

TAKING ON THE OPIOID OVERDOSE EPIDEMIC IN NEW JERSEY

August 3, 2023 | msn.com

UK drugmaker Hikma raises annual outlook for generics arm

August 3, 2023 | marketwatch.com

Hikma Pharmaceutical 1H EPS 59.0c

August 3, 2023 | nasdaq.com

Hikma Pharma H1 Profit Down, Revenues Up; Lifts FY23 Forecast For Generics

July 27, 2023 | finance.yahoo.com

Octave Bioscience Closes $30M Extension to Series B Funding

July 25, 2023 | finance.yahoo.com

Inhalation Anesthesia Global Market Report 2023: Technological Advancements Driving Strong Growth in the Industry

July 24, 2023 | cnbc.com

'Good value, low risk, high quality': BofA names top Europe stocks to beat a recession

July 21, 2023 | finance.yahoo.com

Major Players Abbott, Pfizer, and Novartis Drive Growth in Global Hormone Therapy Market to 2032

See More Headlines

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Ex-Dividend for 9/15 Dividend: 8/10/2023
Dividend Payable: 9/15/2023
Today: 9/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:HIK
CUSIP: N/A
CIK: N/A
Web: www.hikma.com
Phone: +44-20-73992760
Fax: N/A
Employees: 8,700
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 1,939.17
High Stock Price Forecast: GBX 2,125
Low Stock Price Forecast: GBX 1,740
Forecasted Upside/Downside: -8.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 0.53
Trailing P/E Ratio: 3,981.13
Forward P/E Ratio: 12.99
P/E Growth: 1.91
Net Income: £146 million
Net Margins: 5.35%
Pretax Margin: N/A
Return on Equity: 6.74%
Return on Assets: 8.06%

Debt

Debt-to-Equity Ratio: 59.58
Current Ratio: 1.79
Quick Ratio: 1.27

Sales & Book Value

Annual Sales: £2.73 billion
Price / Sales: 1.71
Cash Flow: GBX 253.03 per share
Price / Cash Flow: 8.34
Book Value: GBX 990 per share
Price / Book: 2.13

Miscellaneous

Outstanding Shares: 221,010,000
Free Float: N/A
Market Cap: £4.66 billion
Optionable: Not Optionable
Beta: 0.43

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Mazen Samih Taleb Darwazah (Age 65)
Exec. Vice Chairman & Pres of MENA
Comp: $1.95M

Mr. Riad Mishlawi
Chief Exec. Officer

Mr. Khalid Waleed Hosny Al Nabilsi (Age 51)
Chief Financial Officer

Mr. Guy Featherstone
Associate Director of Investor Relations

Mr. Hussein Omar Arkhagha
Company Sec. & Chief Counsel

Mr. Bassam Wael Rushdi Kanaan CFA (Age 58)
CPA, Exec. VP of Corp. Devel. and M&A

Ms. Susan Ringdal
Exec. VP of Strategic Planning & Global Affairs

Ms. Majda Labadi
Exec. VP of Organisational Devel.

Mr. Brian Hoffmann
Pres of Generics

Mr. Samuel Park
Global Head of Intellectual Property (IP) & Gen. Counsel for US

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares.
View HIK analyst ratings or view top-rated stocks.
What is Hikma Pharmaceuticals' stock price forecast for 2023?: 6 brokers have issued 12 month price objectives for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,740 to GBX 2,125. On average, they anticipate the company's share price to reach GBX 1,939.17 in the next twelve months. This suggests that the stock has a possible downside of 8.1%.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.
How have HIK shares performed in 2023?: Hikma Pharmaceuticals' stock was trading at GBX 1,552 at the beginning of the year. Since then, HIK stock has increased by 36.0% and is now trading at GBX 2,110.
View the best growth stocks for 2023 here.
How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?: Hikma Pharmaceuticals declared a dividend on Thursday, August 3rd. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 0.25 per share on Friday, September 15th. This represents a yield of 0.95%. The ex-dividend date is Thursday, August 10th. The official announcement can be viewed at this link.
Read our dividend analysis for HIK.
Is Hikma Pharmaceuticals a good dividend stock?: Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 49 per share and currently has a dividend yield of 2.37%. The dividend payout ratio is 9,245.28%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.
What other stocks do shareholders of Hikma Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?: Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."
How do I buy shares of Hikma Pharmaceuticals?: Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Hikma Pharmaceuticals' stock price today?: One share of HIK stock can currently be purchased for approximately GBX 2,110.
How much money does Hikma Pharmaceuticals make?: Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £4.66 billion and generates £2.73 billion in revenue each year. The company earns £146 million in net income (profit) each year or GBX 0.53 on an earnings per share basis.
How many employees does Hikma Pharmaceuticals have?: The company employs 8,700 workers across the globe.
How can I contact Hikma Pharmaceuticals?: Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hikma Pharmaceuticals (HIK) Share Forecast, Price & News

Hikma Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Hikma Pharmaceuticals (LON:HIK) Stock

HIK Price History

HIK Stock News Headlines

HIK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

HIK Stock - Frequently Asked Questions

Overall MarketRank^™